Biocon Limited (BOM: 532523)
India
· Delayed Price · Currency is INR | Market Cap | 402.07B |
| Revenue (ttm) | 148.94B |
| Net Income (ttm) | 14.39B |
| Shares Out | n/a |
| EPS (ttm) | 12.00 |
| PE Ratio | 27.94 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 72,049 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 244.40 - 395.65 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 29, 2025 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
Pharma stocks: Divi’s Lab (+0.82%), IPCA (+0.83%) rise; Biocon (-1.86%), Glaxo (-1.44%) decline
The pharma sector showed a mixed trend during intraday trading as of 11:25 AM, with select stocks gaining while others faced selling pressure. Key Performances: Gaining Stocks: IPCA Laboratories: Up 0...
Pharma Stocks: Cipla down nearly 2%, Ajanta Pharma down 1.45%, Abbott India up 1.27%
The Nifty Pharma index was trading 0.25% lower at 22,389.10 during today’s session, as losses in Cipla, Biocon, and Aurobindo Pharma weighed on the sector, despite gains in Abbott India and Ajanta Pha...
Biocon shares surge nearly 3% after FDA nod for Yesintek, a biosimilar to Stelara
Shares of Biocon surged by 2.7% to Rs 375 on Monday following the U.S. FDA’s approval for Yesintek, a biosimilar to Johnson & Johnson’s blockbuster arthritis drug, Stelara. This approval marks a signi...
Stocks to watch today: Maruti Suzuki, TVS Motor, Biocon, DLF, RVNL, RBL, Cipla, Home First, Cochin Shipyard in focus
The stock market is abuzz with updates across several companies today. Below are the highlights in the green and red zones: Maruti Suzuki: November sales saw a minor beat, driven by a strong performan...
Pharma stocks weekly roundup: Biocon leads with 9.08% gain, Torrent Pharma up 4.91%, Lupin dips 1.82%
The pharmaceutical sector experienced diverse movements during the week of November 25–29, 2024. Among the notable performers, Biocon Ltd led the gains with a significant surge of ₹30.35 (9.08%), clos...
Biocon shares surge over 3% after Bengaluru facilities get VAI Tag from USFDA
Biocon Ltd. saw its shares rise by more than 3% in early trading after the U.S. Food and Drug Administration (USFDA) issued a “Voluntary Action Indicated” (VAI) tag to the manufacturing facilities of ...
Stocks to watch today: Divi’s Laboratories, JSW Steel, LIC, Biocon in focus; Asian Paints, Tata Motors, Aurobindo Pharma, Ola Electric under pressure
In today’s market action, key stocks to watch include Divi’s Laboratories, which reported better-than-expected results, and JSW Steel, which has been chosen as the preferred bidder for new coal blocks...
Access to healthcare will remain a priority for the US, says Biocon CEO
Peter Bains, Group CEO of Biocon, talks about how the India-based pharmaceutical company is placed ahead of a second Trump presidency, as well as the development of its weight-loss and anti-obesity dr...
Pharma Sector Stocks: Granules down 1.68%, Akums slips 1.29%, Zydus Life up 0.13%, Aurobindo Pharma gains 0.99% in early trade
Time Stamp: November 4, 2024, 9:41 AM Market Update: Pharma stocks opened with a mixed trend today, showing slight gains and losses among the major players. SPARC: Down by 1.81%, trading at ₹212.04 PP...
Stocks to watch today: L&T, Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon post Q2 results – Brokerage reports inside
Several leading companies, including Larsen & Toubro (L&T), Voltas, Dabur, Aditya Birla Capital, Tata Power, and Biocon, announced their Q2 FY25 results yesterday. Here’s a look at their performance, ...
Biocon Q2 FY25 Results: Company posts net loss of Rs 16 crore, Revenue flat at Rs 3,623 crore
Biocon reported a net loss of ₹16 crore for the period, attributed to higher tax expenses resulting from a geographical shift in profits and minority interest.
Stocks to watch today as key Q2 FY24-25 results roll in: L&T, Tata Power, Dabur, PGHH, Biocon, Aditya Birla Capital and more
Today is set to be an active trading day with several prominent companies scheduled to release their Q2 FY24-25 earnings. Investors will be closely analyzing these results to gauge company performance...
HSBC on Biocon: Reduce call, sees 7.8% downside from current share price
HSBC has maintained its reduce rating on Biocon, lowering the share price target to ₹300, implying a 7.8% downside from the current market price (CMP). A positive court ruling positions Amgen well for...